Legend Biotech Q2 2023 Earnings Report $38.10 +0.26 (+0.70%) As of 02:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast Legend Biotech EPS ResultsActual EPS-$0.57Consensus EPS -$0.36Beat/MissMissed by -$0.21One Year Ago EPSN/ALegend Biotech Revenue ResultsActual Revenue$73.30 millionExpected Revenue$56.64 millionBeat/MissBeat by +$16.66 millionYoY Revenue Growth+510.80%Legend Biotech Announcement DetailsQuarterQ2 2023Date8/15/2023TimeBefore Market OpensConference Call ResourcesPress ReleaseLEGN Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Legend Biotech Earnings HeadlinesHere’s Why Legend Biotech Corporation (LEGN) Will Double in 2025January 31, 2025 | msn.comQ4 EPS Estimates for Legend Biotech Boosted by HC WainwrightJanuary 28, 2025 | americanbankingnews.com Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!February 5, 2025 | Paradigm Press (Ad)Legend Biotech's SWOT analysis: carvykti's efficacy drives stock potential amid competitionJanuary 27, 2025 | msn.comBarclays Keeps Their Buy Rating on Legend Biotech (LEGN)January 27, 2025 | markets.businessinsider.comStrong Buy Recommendation for Legend Biotech Amidst Robust Sales and Strategic ExpansionsJanuary 23, 2025 | markets.businessinsider.comSee More Legend Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Legend Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Legend Biotech and other key companies, straight to your email. Email Address About Legend BiotechLegend Biotech (NASDAQ:LEGN), a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.View Legend Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Earnings Miss? Amgen’s Dividend Still a Bright SpotPalantir Stock Surges After Blockbuster Earnings: What's Next?Atlassian: Upside Still in Play After Impressive Earnings SpikeWhy Amazon’s Next Earnings Could Trigger a Stock BreakoutS&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After Earnings Upcoming Earnings AstraZeneca (2/6/2025)Fortinet (2/6/2025)Amazon.com (2/6/2025)Linde (2/6/2025)Sumitomo Mitsui Financial Group (2/6/2025)ING Groep (2/6/2025)ConocoPhillips (2/6/2025)KKR & Co. Inc. (2/6/2025)Intercontinental Exchange (2/6/2025)Thomson Reuters (2/6/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
